164 related articles for article (PubMed ID: 33156704)
1. Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre.
Robson H; Braund R; Glass M; Ashton J; Tatley M
Clin Toxicol (Phila); 2021 Jun; 59(6):472-479. PubMed ID: 33156704
[TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.
Kunac DL; Harrison-Woolrych M; Tatley MV
N Z Med J; 2008 Oct; 121(1283):76-89. PubMed ID: 18841188
[TBL] [Abstract][Full Text] [Related]
3. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
[No Abstract] [Full Text] [Related]
5. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
[TBL] [Abstract][Full Text] [Related]
6. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
Hobbs M; Kalk NJ; Morrison PD; Stone JM
Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
[TBL] [Abstract][Full Text] [Related]
8. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
Timmerman A; Balcaen M; Coopman V; Degreef M; Pottie E; Stove CP
Harm Reduct J; 2024 Jul; 21(1):127. PubMed ID: 38951904
[TBL] [Abstract][Full Text] [Related]
9. [Adverse drug reactions (ADRs) to antimalarial drugs. Analysis of spontaneous report from the French pharmacovigilance database (1996-2000)].
Angles A; Bagheri H; Montastruc JL; Magnaval JF;
Presse Med; 2003 Jan; 32(3):106-13. PubMed ID: 12610379
[TBL] [Abstract][Full Text] [Related]
10. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
Smith KE; Staton M
Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
[No Abstract] [Full Text] [Related]
11. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015.
Cordeiro SK; Daro RC; Seung H; Klein-Schwartz W; Kim HK
Addiction; 2018 Oct; 113(10):1850-1861. PubMed ID: 29806885
[TBL] [Abstract][Full Text] [Related]
12. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
Zaurova M; Hoffman RS; Vlahov D; Manini AF
J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136
[TBL] [Abstract][Full Text] [Related]
13. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
Waters ML; Dargan PI; Yates C; Dines AM; Eyer F; Giraudon I; Heyerdahl F; Hovda KE; Liechti ME; Miró Ò; Vallersnes OM; Anseeuw K; Badaras R; Bitel M; Bonnici J; Brvar M; Caganova B; Calýskan F; Ceschi A; Chamoun K; Daveloose L; Galicia M; Gartner B; Gorozia K; Grenc D; Gresnigt FMJ; Hondebrink L; Jürgens G; Konstari J; Kutubidze S; Laubner G; Liakoni E; Liguts V; Lyphout C; McKenna R; Mégarbane B; Moughty A; Nitescu GV; Noseda R; O'Connor N; Paasma R; Ortega Perez J; Perminas M; Persett PS; Põld K; Puchon E; Puiguriguer J; Radenkova-Saeva J; Rulisek J; Samer C; Schmid Y; Scholz I; Stašinskis R; Surkus J; Van den Hengel-Koot I; Vigorita F; Vogt S; Waldman W; Waring WS; Zacharov S; Zellner T; Wood DM
Clin Toxicol (Phila); 2024 Jun; ():1-7. PubMed ID: 38934347
[TBL] [Abstract][Full Text] [Related]
14. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
[TBL] [Abstract][Full Text] [Related]
15. Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre.
Shalviri G; Yousefian S; Gholami K
J Clin Pharm Ther; 2012 Aug; 37(4):448-51. PubMed ID: 22122488
[TBL] [Abstract][Full Text] [Related]
16. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
Alam RM; Keating JJ
Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
[TBL] [Abstract][Full Text] [Related]
17. Patients' Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana.
Sabblah GT; Darko DM; Mogtari H; Härmark L; van Puijenbroek E
Drug Saf; 2017 Oct; 40(10):911-921. PubMed ID: 28653291
[TBL] [Abstract][Full Text] [Related]
18. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
19. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
Cairns R; Brown JA; Gunja N; Buckley NA
Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
[TBL] [Abstract][Full Text] [Related]
20. Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014.
Awodele O; Ibrahim A; Orhii P
Int J Risk Saf Med; 2016 Mar; 28(1):13-23. PubMed ID: 27176753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
